Breaking

Taiwan plans to cull up to 120,000 green iguanas due to their negative impact on agriculture
UK teenager jailed for minimum of 52 years for Southport girls’ murders
Palestinian journalist reunited with child after harrowing months in Israeli jail
Amanda Knox slander conviction upheld by Italy’s high court
‘Bomb’ cyclone Storm Éowyn approaches Ireland and parts of UK as schools and public transport shut
Trump 2.0 is going well for China so far. But can the honeymoon last?
Death sentence for Chinese knife attacker who stabbed Japanese mother, child
Israel seeks to remain in Lebanon past Sunday withdrawal deadline

Home
Features
- View All On Demos
Buy Now
Search for:

Investing

RAD 202 receives approval to start Phase 1 therapeutic trial

December 20, 2024

Share on Facebook Share on Twitter Pinterest LinkedIn Tumblr Email

Share

Share on Facebook Share on Twitter Pinterest Email

Radiopharm Theranostics (RAD:AU) has announced RAD 202 receives approval to start Phase 1 therapeutic trial

Download the PDF here.

This post appeared first on investingnews.com

0

Related Posts

Platinum Price Forecast: Top Trends for Platinum in 2025

January 24, 2025

Altech Batteries LtdCERENERGY Accredited Highest Possible Green Rating

January 24, 2025

Trump Revives Tariff Threats Against EU and China, Targeting Trade and Fentanyl Crisis

January 24, 2025

Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.

Your name

Your email

By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.
Categories
- Business (171)
- Investing (514)
- Stocks (194)
- World (631)

Disclaimer: thecapitalstrategies.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.
Latest

Copyright © 2025 thecapitalstrategies.com | All Rights Reserved

Top

Type above and press Enter to search. Press Esc to cancel.